Maurie Markman, MD, discusses conflicts of interest in cancer care.
Commentary|Articles|March 31, 2025
The Long-Term Impact of COVID-19 on Oncology Care: A Five-Year Retrospective
Author(s)Courtney Flaherty
Fact checked by: Caroline Seymour
Experts across specialties reflect on the long-term effects of COVID-19 on several aspects of cancer care.
Advertisement
Advertisement
Five years after the onset of the COVID-19 pandemic, the oncology field continues to grapple with its repercussions. From fundamental shifts in patient management, including the introduction of telemedicine, to trial disruptions and workforce challenges, the pandemic has reshaped every aspect of oncology care. Although some of these adaptations offer unique benefits, others require strategic solutions, and the oncology community must continue to adapt and innovate to ensure optimal patient outcomes.
Related to this article
In an OncLive Peer Exchange, experts discussed the evolving treatment landscape in CLL, spanning frontline selection to emerging next-generation agents.
New research explains what triggers liposarcoma cells to become more or less aggressive and identifies potential targets for aggressive tumors.
The FDA has issued a CRL to the NDA seeking the approval of the investigational agent 177Lu-edotreotide for the treatment of patients with GEP-NETs.
Divesiran significantly increased the proportion of clinical responders vs placebo in phlebotomy-dependent polycythemia vera.
Leonard J. Appleman, MD, PhD, discusses prior data with SYNC-T Therapy SV-102 and the ongoing LEGION-100 study in prostate cancer.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
The top 5 OncLive TV videos of the week cover insights in melanoma, prostate cancer, breast cancer, multiple myeloma, and small cell lung cancer.
Advertisement
Advertisement